【摘要】 目的探讨西酞普兰联合利培酮治疗难治性抑郁症的安全性和疗效。方法将69例难治性抑郁症患者随即分为两组,研究组采用西酞普兰联合利培酮治疗,对照组仅用西酞普兰治疗。两组作4周治疗观察。于入组前及入组后第2、4周末分别用汉密尔顿抑郁量表(HAMA),汉密尔顿焦虑量表(HAMA)及不良反应量表进行评定。结果两组在治疗后第1、2及4周末HAMD、HAMA总分及减分率的差异有统计学意义,两组间有效率的差异也有统计学意义。药物不良反应两组间无明显差异。结论西酞普兰联合利培酮治疗难治性抑郁症疗效要明显优于单独西酞普兰治疗(P<0.05),药物不良反应两组间无明显差异(P>0.05)。更多还原

【Abstract】 Objective To study the therapeutic and side effects of citalopram combined with risperidone for patients with treatment-resistant depression.Methods A total of 69 patients with the treatment-resistant depression were randomly assigned to the two groups:risperidone with citalopram or citalopram or citalopram alone.They were evaluated with Hamilton Depression Scale(HAMD),Hamilton Anxiety Scale(HAMA),and Treatment Emergent Symptom Scale(TESS)before treatment and at the end of 1st,2nd,4th week after treatment.The study last for 4 weeks.Results There were significant difference on the scores of HAMD and HAMA between the uwo groups at the end of 2nd and 4th week after treatment.The effective rate had significant difference between two groups.There was no significant difference in side effects between two groups.Conclusion Citalopram combined with risperidone is an efficacious and safe strategy for treatment-resistant depression.更多还原